Addressing current challenges in cancer immunotherapy with mathematical and computational modeling
Clicks: 88
ID: 281544
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
26.1
/100
88 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #292 of 803 articles by views in arXiv
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 803 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The goal of cancer immunotherapy is to boost a patient's immune response to a
tumor. Yet, the design of an effective immunotherapy is complicated by various
factors, including a potentially immunosuppressive tumor microenvironment,
immune-modulating effects of conventional treatments, and therapy-related
toxicities. These complexities can be incorporated into mathematical and
computational models of cancer immunotherapy that can then be used to aid in
rational therapy design. In this review, we survey modeling approaches under
the umbrella of the major challenges facing immunotherapy development, which
encompass tumor classification, optimal treatment scheduling, and combination
therapy design. Although overlapping, each challenge has presented unique
opportunities for modelers to make contributions using analytical and numerical
analysis of model outcomes, as well as optimization algorithms. We discuss
several examples of models that have grown in complexity as more biological
information has become available, showcasing how model development is a dynamic
process interlinked with the rapid advances in tumor-immune biology. We
conclude the review with recommendations for modelers both with respect to
methodology and biological direction that might help keep modelers at the
forefront of cancer immunotherapy development.
| Reference Key |
laubenbacher2017addressing
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Anna Konstorum; Anthony T. Vella; Adam J. Adler; Reinhard Laubenbacher |
| Journal | arXiv |
| Year | 2017 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.